Clinical Trial

The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2025 (before its estimated April 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the effectiveness and safety of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in peritoneal metastatic pancreatic cancer. The main question it aims to answer are: (1) Does this combined approach increase 1-year survival rates? and (2) What is the safety profile of this treatment regimen? Participants will: undergo baseline imaging and surgical exploration to confirm peritoneal metastasis, receive two cycles of intraperitoneal cisplatin HIPEC (70mg/m²) postoperatively, followed by systemic AG chemotherapy (nab-paclitaxel plus gemcitabine), with treatment adjustments based on regular imaging assessments and multidisciplinary team (MDT) recommendations.
Trial Details
NCT Number NCT06946901
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer
Enrollment 90 participants
Start Date 2025-04-03
Primary Completion 2026-04-03 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-27